Senseonics Holdings/$SENS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Senseonics Holdings
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
- Ticker
- $SENS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 130
- Headquarters
- Germantown, United States
- Website
- www.senseonics.com
SENS Metrics
BasicAdvanced
$571M
-
-$2.29
1.03
-
Price and volume
Market cap
$571M
Beta
1.03
52-week high
$13.98
52-week low
$4.79
Average daily volume
806K
Financial strength
Current ratio
5.923
Quick ratio
5.428
Long term debt to equity
0.761
Total debt to equity
0.805
Interest coverage (TTM)
-20.75%
Profitability
EBITDA (TTM)
-118.662
Gross margin (TTM)
58.72%
Net profit margin (TTM)
-204.19%
Operating margin (TTM)
-200.98%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-49.85%
Return on equity (TTM)
-157.32%
Valuation
Price to revenue (TTM)
9.331
Price to book
7.35
Price to tangible book (TTM)
7.35
Price to free cash flow (TTM)
-4.856
Free cash flow yield (TTM)
-20.59%
Free cash flow per share (TTM)
-2.146
Growth
Revenue change (TTM)
104.83%
Earnings per share change (TTM)
38.91%
3-year revenue growth (CAGR)
44.40%
10-year revenue growth (CAGR)
100.91%
3-year earnings per share growth (CAGR)
4.60%
10-year earnings per share growth (CAGR)
-15.27%
What the Analysts think about SENS
Analyst ratings (Buy, Hold, Sell) for Senseonics Holdings stock.
Analyst projections of the future price of Senseonics Holdings stock.
Bulls say / Bears say
Third-quarter revenue rose 140% year on year to $19.6 million, and Senseonics lifted its 2026 revenue forecast to $68 million–$70 million. This points to accelerating demand for Eversense 365 after the company took its US sales operation in-house. (GlobeNewswire)
Gross margin reached about 62% in the third quarter, and the company now expects more than 60% for the full year. Better margins could help the business capture more value as it expands its own commercial operation. (GlobeNewswire, The Motley Fool)
Eversense 365 offers a year-long sensor, and Senseonics is widening its reach through pump integrations: its twiist partnership is gaining traction, with an iLet launch planned for the fourth quarter. The early-stage Freedom study could add longer-term upside if the company develops a CGM without on-body hardware. (The Motley Fool, GlobeNewswire)
The business remains deeply loss-making: its third-quarter net loss widened to $32.7 million, while operating expenses more than doubled. Management expects full-year cash use of about $120 million and operating expenses above its previous range. (The Motley Fool, Drug Delivery Business News)
Senseonics has relied on external financing while it burns cash: it raised more than $100 million through an equity offering and an amended credit facility in the first half of 2026. That leaves shareholders exposed to further dilution and the company carrying debt before it reaches profitability. (SEC)
Growth is heavily concentrated in the US: third-quarter US revenue was $16.8 million, against $2.8 million internationally. The company now expects markets outside the US to provide about 15% of 2026 revenue, below its earlier 20% expectation, leaving the international expansion and commercial transition as execution risks. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
SENS Financial Performance
Revenues and expenses
SENS Earnings Performance
Company profitability
Upcoming events
No upcoming events
SENS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.